МИЕЛОДИСПЛАСТИЧЕСКИЙ СИНДРОМ
Аннотация
Миелодиспластический синдром
Библиографические ссылки
1. Cheson B.D. The Myeloblastic Syndromes // The Oncologist-1997-vol.2.P.28-39.
2. Mufti G., List A.F., Gore S.D., Ho A.Y. Myeloblastic syndromes //Hematology (Amer.Soc.Hematol. Educ. Program) .-2003. P.176-194
3. Greenberg P.L., Young N.S., Gattermann N. Myeloblastic Syndromes //Hematology (Amer.Soc.Hematol. Educ. Program). -2002.P.136-161
4. List A.F. New approaches to treatment of Myelodysplasia // The Oncologist.-1997.-Vol.2.-P.389-401.
5. Pradhan A., Mijovic A., Mills K. et al. Genes differentially expressed in adult familial myelodysplastic syndromes (MDS). Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 6.
6. Kozarezova T., Klimkovich N. Some epidemiological aspects MDS at children of Belarus. Clinical and Laboratory Studies 7-th International Symposium on Myelodysplastic Syndromes, 2003, abstr. P. 6.
7. Филина О.Ю. и соавт. Миелодиспластические заболевания у детей: варианты клинического течения и биологические особенности кроветворения. Часть 3. Метод проточной цитометрии и дифференциальной диагностики (Гематология и трансфузиология -2003.- Т.50, №3.-3-23).
8. Heim S., Mitelman F. Cromosome abnormalities in the myelodysplastic sy ndromes. Clin. Hematol. 1986. Vol. 15. P. 1003 1021.
9. Mufti G.J. Chromosomal deletions in the myelodysplastic syndrome. Leukemia Research, 1992, Vol. 16, №1, P. 35-41.
10. Kaneko H., Misawa S, Horiike S. TP53 mutations emerge at early phase of myelodysplasia syndrome and are associated with complex chromosomal abnormalities. Blood, 1995, Vol. 85, №8, P. 2189-2193.
11. Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia, 2000, №14, P. 2-8.
12. Look A.T. Molecular pathogenesis of MDS //Hematology (Amer.Soc.Hematol. Educ. Program Book).-2005.-P.156-160.
13. Мамаев Н.Н. Патогенез миелодиспластического синдрома в свете цитогенетических и молекулярно-биологических характеристик кроветворных элементов //Юбилейный сборник научных работ кафедры факультетской терапии.- СПБ., 2000.-с. 319-326.
14. Nossinger Th. et al. Myelodysplastic syndroms, from French-American-British to World Helth Organization: compazison of classifications on 431 unselected patients from a single institution //Blood.-2001.-Vol.98.№ 10.-P. 2935-2941.
15. Gupta P., Niehans G., LeRoy S. et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia, 1999,№13, P. 44-53.
16. Гладыш В.В. Клиника и диагностика идиопатических миелодиспластических синдромов (рефрактерных анемий): Авто-реф. дис. канд. мед. наук. М., 1998.
17. Beran M., Estey E., O'Brien S. et al. Topotecan and cytarabine is an active combination regimen in myeiodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin Oncol. ,1999, Vol.17, № 9, P.2819-2830.
18. Van den Berghe J., Vermaelen K., Mecucci C. et.al. The 5q-anomaly // Cancer Genet. Cytogenet.-1985.-Vol.17.-P.189-255.
19. Boultwood J., Pellagatti A., McKenzie A.N.J., Waincoat J.S. Advances in the 5q- syndrome // Blood.-2010.-Vol.116.-P. 5803-. 5811.
20. Савченко В.Г., Паровичникова E.H., Михайлова Е.А. и др. Миелодиспластический синдром: некоторые вопросы патогенеза и лечения. Терапевтический архив, 1996, том 68, №7, стр. 34-37.
21. Ширин А.Д., Волкова М.А., Френкель М.А. Миелодиспластические синдромы. Клиническая онкогематология. Москва 2001 г., стр. 214 -236.
22. Zouchauer S., Gsur A., Gotzl M. etal. MDR1 gene expression in myelodysplastic syndrome and in acute myeloid leukemia evolving from myelodysplastic syndrome. Anticancer Res, 1994,Vol 14, №3B, P. 1293-1295.
23. Bartl R., Frisch B., Baumgart R. Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephinebiopsies. Leukemia Research, 1992, Vol.l6,№l, P. 1533.
24. Георгии А., Бюр Т., Машек X. и др. Гистопатология миелодиспластического синдрома: вопросы диагностики, гипопластический вариант и проблемы вторичного МДС. Гематология и трансфузиология, 1995, №2, стр. 11.
25. Зумбос Н. К. вопросу о взаимоотношении апластической анемии и миелодиспластического синдрома. Гемат. и трансфуз., 1999, №4, стр.2325.
26. Greenberg P.L. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes //Blood.-1997.-Vol.89.-P. 2079-2088.
27. Fenaux P., Morel P., Rose C. et al. Prognostic factors in adult de novo myelody splastic syndromes treated by intensive chemotherapy. Br. J. Haemat. 1991,Vol. 77, P.497-501.
28. Trigot G. J. Prognostic factors in the myelodysplastic syndromes. Leukemia Research, 1992, Vol. 16, №1, P. 109-115.
29. Hofman W., Ganser A., Seipeit G. et al. Treatment op patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferonalpha, and gpanulocyte colony -stimulating factor. Ann Hematol., 1999, Vol. 73, №3,P. 12-30.
30. List A.F. et al. Myeloblastic Syndromes //Hematology.-2004.P.1123-1136.
31. Garg R.. Faderi S.. Garcia-Manero G., etal. Phase IL. Studu of, rabbit antitymocyte globulin cyclosporine and granulocyte colony-stimulating factor in patients with Aplastik Anemia and myeloblastik sy ndrome. Lenkemia 2009; 23(7):1297-1302.
32. Kadia T., Ravandi F., Garcia-Fanero G., etal., Updated zesults of combination cytokine ummonotherapy in the treatment of Aplastis Anemia and mylodisplastic syndrome (MDS) (abstract). Blood (ASH Annual Meeting Abstracts) 2010; 116(21):2920.
33. Sanz M.A., Sanz G., Vallespi T.A patient- oriented approach to treatment of myelodysplastic syndrome // Hematologica.- 1998.- Vol. 83, P. 910-935.
34. Appelbaum S., Anderson M. And J. allogenic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia, 1998, Vol.12, suppl.l, P.25-29.
35. Janasova A., Neuwirtova R., Cermak J. et al. Cyclosporin A therapy in hyp oplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br. J. Haematol., 1998,Vol. 100, P. 304-309.
36. Luger S.,Sacks N. Bone marrow transplantation for myelodysplastic syndrome- Who? When? And Which? // Bone marrow transplant.-2002.-Vol.30.№ 4.-P. 199-206.
37. Gastro-Malaspina H. et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program // Blood.-2002. Vol. 99 №6.P.1943-1951.
38. Saba H.T. Decitabine in the treatment of myelodysplastic syndromes // Ther. Clin.Rick. Manag.- 2007.- Vol.3 (#5).-P.807-817.
